MedTrace Logo

The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

NCT00518102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4431

Last updated 2016-07-19

No results posted yet for this study

Summary

The purpose of this study is to compare the risk of cancers in patients who have used REGRANEX (becaplermin) to that of patients with similar characteristics and health issues who have not used REGRANEX (becaplermin). REGRANEX (becaplermin) is topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes.

Conditions

Interventions

DRUG

REGRANEX (becaplermin)

A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).

OTHER

REGRANEX (becaplermin) comparators

A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)

Sponsors & Collaborators

  • Ethicon, Inc.

    lead INDUSTRY

Principal Investigators

  • Ethicon, Inc. Clinical Trial · Ethicon, Inc.

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518102 on ClinicalTrials.gov